- Home
- PGRE vs COGT Comparison
PGRE vs COGT Comparison
Compare PGRE & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGRE
- COGT
- Stock Information
- Founded
- PGRE 1978
- COGT 2014
- Country
- PGRE United States
- COGT United States
- Employees
- PGRE N/A
- COGT N/A
- Industry
- PGRE Real Estate Investment Trusts
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- PGRE Real Estate
- COGT Health Care
- Exchange
- PGRE Nasdaq
- COGT Nasdaq
- Market Cap
- PGRE 1.0B
- COGT 900.3M
- IPO Year
- PGRE 2014
- COGT 2018
- Fundamental
- Price
- PGRE $4.80
- COGT $7.84
- Analyst Decision
- PGRE Hold
- COGT Buy
- Analyst Count
- PGRE 3
- COGT 6
- Target Price
- PGRE $4.50
- COGT $14.20
- AVG Volume (30 Days)
- PGRE 1.0M
- COGT 1.8M
- Earning Date
- PGRE 02-12-2025
- COGT 11-12-2024
- Dividend Yield
- PGRE 2.18%
- COGT N/A
- EPS Growth
- PGRE N/A
- COGT N/A
- EPS
- PGRE N/A
- COGT N/A
- Revenue
- PGRE $553,641,000.00
- COGT N/A
- Revenue This Year
- PGRE N/A
- COGT N/A
- Revenue Next Year
- PGRE N/A
- COGT N/A
- P/E Ratio
- PGRE N/A
- COGT N/A
- Revenue Growth
- PGRE N/A
- COGT N/A
- 52 Week Low
- PGRE $4.21
- COGT $4.28
- 52 Week High
- PGRE $5.47
- COGT $12.61
- Technical
- Relative Strength Index (RSI)
- PGRE 46.84
- COGT 31.99
- Support Level
- PGRE $4.80
- COGT $7.30
- Resistance Level
- PGRE $4.97
- COGT $8.56
- Average True Range (ATR)
- PGRE 0.16
- COGT 0.67
- MACD
- PGRE -0.01
- COGT -0.08
- Stochastic Oscillator
- PGRE 45.45
- COGT 16.77
About PGRE Paramount Group Inc.
Paramount Group Inc is a real estate investment trust engaged in owning, operating, managing, acquiring, and redeveloping high-quality, Class A office properties in select central business district (CBD) submarkets of New York City and San Francisco. The company operates in two geographical segments New York and San Francisco. Paramount Group derives nearly all of its revenue in the form of rental income from leasing its offices to tenants.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.